ArticlePLoS pathogens2025
HIV-1 Vpr orchestrates ciTRAN upregulation through TGF-β induction.
Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CircRNA0857 acts as an miRNA sponge to promote Newcastle disease virus replication via modulating autophagy.Journal of virology · 2026Article
- Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond.Signal transduction and targeted therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Circular RNA (circRNA) expression is widespread in immune cells infected by HIV-1, but the crosstalk between circRNA expression and various cellular signaling pathways remains elusive. Here, we report that HIV-1 Vpr can induce the production of TGF-β during infection, which we linked to the upregulation of ciTRAN, a proviral circRNA encoded by SMARCA5. Consistent with this finding, we observed that the essential intracellular TGF-β receptor signaling component SMAD2/3 was recruited to the SMARCA5 promoter in a Vpr-dependent manner. SMARCA5 promoter analysis and functional assays further revealed that SAMD2/3 binding motif in the SMARCA5 promoter is crucial for ciTRAN upregulation. Notably, in response to treatment with DNA-damaging agents or the exogenous addition of recombinant TGF-β, the TGF-SMAD axis upregulated the expression of ciTRAN as well as the parental SMARCA5 mRNA. Regardless, the QKI protein was necessary for ciTRAN biogenesis. Finally, pharmacological targeting or genetic ablation of TGFBR1 can reduce the ability of Vpr to promote the expression of ciTRAN and viral genes. These results highlight the TGF-β-mediated regulation of ciTRAN expression which may play a role in modulating HIV-1 replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.